Member access

4-Traders Homepage  >  Shares  >  London Stock Exchange  >  GlaxoSmithKline plc    GSK   GB0009252882

Delayed Quote. Delayed London Stock Exchange - 04/17 11:35:23 am
1559 GBp   -0.29%
4h ago AstraZeneca cancer pipeline seen as draw for Pfizer
1d ago Pfizer considers $100 billion bid for AstraZeneca
3d ago GLAXOSMITHKLINE : Assigned Patent
SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 

GlaxoSmithKline plc : Transaction in Own Shares

12/11/2013 | 01:34pm US/Eastern
Recommend:
0

?

GlaxoSmithKline plc (the Company) announces that in accordance with the authority granted by shareholders at the Company's Annual General Meeting on 1 May 2013 it purchased 317,000 of its Ordinary Shares of 25 pence each (Shares) on 11 December 2013.

The highest price paid per Share was 1582.00 pence per Share.

The lowest price paid per Share was 1577.00 pence per Share.

The Company intends to hold these Shares in Treasury.

The Company holds 515,018,909 of its Shares in Treasury, representing 9.59% of the total issued share capital of the Company.

Including Shares which have been purchased but not yet settled, the Company holds 516,339,909 of its Shares in Treasury, representing 10.63% of the total voting rights in the Company.

The Company has 4,856,845,827 Shares in issue (excluding Shares held in Treasury). This number represents the total voting rights in the Company and may be used by shareholders as the denominator for the calculations by which they can determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

This announcement does not constitute, or form part of, an offer or any solicitation of an offer to purchase or subscribe for securities in any jurisdiction and is in conformity with the Financial Conduct Authority's Disclosure and Transparency Rules.


This information is provided by RNS
The company news service from the London Stock Exchange
ENDPOSLLFIDFRLLLIV
distributed by
Recommend :
0
React to this article
Latest news on GLAXOSMITHKLINE PLC
4h ago AstraZeneca cancer pipeline seen as draw for Pfizer
1d ago Pfizer considers $100 billion bid for AstraZeneca
3d ago GLAXOSMITHKLINE : Assigned Patent
3d ago GLAXOSMITHKLINE : GSK and Genmab receive FDA approval for Arzerra (ofatumumab) a..
4d ago GLAXOSMITHKLINE : GSK and Genmab receive FDA approval for Arzerra® (ofatumumab) ..
4d ago China's new breed of whistleblowers takes on big business
4d ago GLAXOSMITHKLINE : GSK announces approval in Canada for Incruse™ Ellipta&tr..
4d agoDJGLAXOSMITHKLINE : GSK Says Incruse Gets Approval in Canada for Treatment of Lung..
4d ago GLAXOSMITHKLINE : GSK announces approval in Canada for Incruse Ellipta (umeclidi..
4d ago GLAXOSMITHKLINE : GSK receives approval in Canada for Incruse
Advertisement
Chart
Duration : Period :
GlaxoSmithKline plc Technical Analysis Chart | GSK | GB0009252882 | 4-Traders
Income Statement Evolution
GlaxoSmithKline plc : Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF